Chen, C., Chen, C., Yan, J.T., Zhou, N., Zhao, J.P., and Wang, D.W. (2020). Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19 (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 48, E008.
Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, D.S.C., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382, 1708–1720.
Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., and Lu, Z. (2020). Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 5, 811.
Henry, B.M., de Oliveira, M.H.S., Benoit, S., Plebani, M., and Lippi, G. (2020). Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 58, 1021–1028.
Huang, W., Li, C., Wang, Z., Wang, H., Zhou, N., Jiang, J., Ni, L., Zhang, X.A., and Wang, D.W. (2020). Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases. Sci China Life Sci https://doi.org/10.1007/s11427-020-1733-4.
Ledford, H. (2020). How does COVID-19 kill? Uncertainty is hampering doctors’ ability to choose treatments. Nature 580, 311–312.
Liu, C., Jiang, Z.C., Shao, C.X., Zhang, H.G., Yue, H.M., Chen, Z.H., Ma, B.Y., Liu, W.Y., Huang, H.H., Yang, J., et al. (2020). Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study (in Chinese). Zhonghua Gan Zang Bing ZaZhi 28, 148–152.
Liu, W., Tao, Z.W., Wang, L., Yuan, M.L., Liu, K., Zhou, L., Wei, S., Deng, Y., Liu, J., Liu, H.G., et al. (2020). Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J 133, 1032–1038.
Ni, L., Zhou, L., Zhou, M., Zhao, J., and Wang, D.W. (2020). Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med 14, 210–214.
Saqrane, S., and El Mhammedi, M.A. (2020). Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. New Microb New Infect 35, 100680.
Yu, B., Li, C., Chen, P., Zhou, N., Wang, L., Li, J., Jiang, H., and Wang, D. W. (2020). Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci https://doi.org/10.1007/s11427-020-1732-2.
We thank all medical staff and medical data managers for data extraction and help for analysis. We would like to thank Prof. Eric H. Xu at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, for his useful suggestion and language improvement in writing this paper. This work was supported in part by the National Key R&D Program of Ministry of Science and Technology of China (2020YFC0844500), National Natural Science Foundation of China (31130031), Emergency Project Fund of Chinese Academy of Sciences (2020YJFK0105), and Chinese Academy of Engineering and Ma Yun Foundation (2020-CMKYGG-05).
Compliance and ethics
The author(s) declare that they have no conflict of interest.
About this article
Cite this article
Yu, B., Li, C., Chen, P. et al. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. Sci. China Life Sci. 64, 330–333 (2021). https://doi.org/10.1007/s11427-020-1782-1